Mira Hellmann, MD | Authors


PARP Inhibitors Advance Beyond Treatment of BRCA1/2-Mutant Gynecologic Cancers

February 04, 2020

Mira Hellmann, MD, discusses how the use of PARP inhibitors as treatment of patients with gynecologic cancers has evolved since they were first introduced into the treatment landscape up to studies evaluating these therapies today in a variety of patient populations, particularly in patients with ovarian cancer.